One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Challenges in antithrombotic treatment and in the management of valvular heart disease
doi : 10.1093/eurheartj/ehaf445
Volume 46, Issue 28, 21 July 2025
Rising demand vs limited access: should cardiologists perform mechanical thrombectomy?
EuroHeart and the National Outcomes Evaluation Programme in Italy: relevance and perspectives
Antithrombotic drugs for acute coronary syndromes in women: sex-adjusted treatment and female representation in randomised clinical trials. A clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and the ESC Working Group on Thrombosis
Antithrombotic treatment following revascularization for chronic limb-threatening ischaemia: a scientific statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy
Bicuspid aortic valve disease: advancements and challenges of transcatheter aortic valve implantation
The year in cardiovascular medicine 2024: the top 10 papers in diabetes and metabolic disorders
Deep learning for echocardiographic assessment and risk stratification of aortic, mitral, and tricuspid regurgitation: the DELINEATE-regurgitation study
Mitral annular disjunction and mitral valve prolapse: long-term risk of ventricular arrhythmias after surgery
Is mitral annular disjunction the cause of arrhythmogenic mitral valve prolapse?
Incidence, risk factors, and mortality of pulmonary embolism in the Netherlands (2015–22): sex differences and shifts during the coronavirus disease 2019 pandemic
From small Dutch cohort studies to large-scale nationwide data: impact of COVID-19 on the risk of pulmonary embolism
Glycoprotein VI inhibitors: glenzocimab and EMA601 two inhibitory Fabs
EMA601 and glenzocimab: two glycoprotein VI inhibitory Fabs with different potency
Quadricuspid aortic valve with partial left coronary sinus isolation
A 14.6 cm paediatric aortic monster: first LOX mutation shattering size records in childhood thoracic aortic aneurysm and dissection
Weekly Journal Scan: is a SMART-CHOICE of clopidogrel monotherapy after coronary stenting supported by adequate evidence?
